Author: Posada-Vergara, MarÃa Paulina; Alzate-Ãngel,, Juan Carlos; MartÃnez-Buitrago, Ernesto
Title: COVID-19 and VIH Cord-id: 5x08lr80 Document date: 2020_6_30
ID: 5x08lr80
Snippet: Throughout the COVID-19 pandemic, the main risk factors associated with the progression to severe disease or death have been typically advanced age, diabetes mellitus, obesity, high blood pressure, heart disease, and chronic pneumopathy. Because of their immunosuppression status, persons with HIV were also expected to have a higher susceptibility to infection or a poor clinical evolution. So far, this has not been confirmed to happen, giving way to hypotheses about the role of immunosuppression
Document: Throughout the COVID-19 pandemic, the main risk factors associated with the progression to severe disease or death have been typically advanced age, diabetes mellitus, obesity, high blood pressure, heart disease, and chronic pneumopathy. Because of their immunosuppression status, persons with HIV were also expected to have a higher susceptibility to infection or a poor clinical evolution. So far, this has not been confirmed to happen, giving way to hypotheses about the role of immunosuppression or the use of antiretrovirals, which could explain this paradox. In this article we present the existing data on the epidemiology and characteristics of HIV-COVID-19 co-infection, discuss the available evidence on the possible factors involved in the evolution of individuals affected by both viruses, analyze other determinants that may negatively affect persons with HIV during the pandemic, and present recommendations for the prevention and care of COVID-19 infection in the context of HIV.
Search related documents:
Co phrase search for related documents- action plan and acute sars severe respiratory syndrome: 1, 2, 3, 4, 5, 6, 7
- action plan and long medium: 1
- action plan and low mortality: 1
- actual burden and acute sars severe respiratory syndrome: 1
- actual burden and lopinavir ritonavir: 1
- acute management and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7
- acute management and low mortality: 1, 2, 3
- acute management and low proportion: 1
- acute respiratory failure and additional risk factor: 1, 2
- acute respiratory failure and lopinavir protease: 1
- acute respiratory failure and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- acute respiratory failure and lopinavir ritonavir addition: 1
- acute respiratory failure and low mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- acute sars severe respiratory syndrome and additional risk factor: 1, 2
- acute sars severe respiratory syndrome and long medium: 1, 2, 3, 4, 5, 6, 7, 8, 9
- acute sars severe respiratory syndrome and long medium term: 1, 2, 3, 4, 5, 6, 7, 8
- acute sars severe respiratory syndrome and lopinavir protease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute sars severe respiratory syndrome and lopinavir protease inhibitor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- acute sars severe respiratory syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
Co phrase search for related documents, hyperlinks ordered by date